TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02533310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OST treatment with in-vivo spiders
Description: Subjects are exposed to phobic stimuli with the aid of a trained psychotherapist during a session of maximum 3 hrs duration. The intensity of exposure is increased in four sequential steps, 1. learning to catch a spider with a glass and paper, 2. touching a spider, 3. letting a spider walk on your hand, 4. letting a spider walk on your body. These stages repeat with increasingly larger spiders. The goal of therapy is not absolute symptom reduction but sufficient reduction to allow the individual to expose themselves in everyday situations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR-OST treatment with virtual spiders
Description: The VR-OST treatment introduces a virtual gamified version of OST treatment using a modern virtual reality headset. Individuals advance themselves through increasing levels of exposure intensity with the assistance of an automated virtual therapist.
Study: NCT00110214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00888537

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AMI Choice Decision Aid
Description: The decision aid describes the risk of dying in the first six months following a heart attack without and with taking a bundle of medications to help the heart heal.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients and clinicians in this arm will discuss medications to help the heart heal after a heart attack in their usual manner.
Study: NCT03436901

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI with DWI vs CT
Description: MRI with diffusion weighted imaging of thorax, abdomen, and pelvis without contrast agent vs. CT of thorax, abdomen, and pelvis with contrast agent
Study: NCT00953810

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational training regarding heart failure
Description: Like control plus one education training regarding heart failure aspects and management
Study: NCT04211454

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study.
Study: NCT01421966

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CureXcell®
Description: CureXcell® injection will be administered about every 4 weeks for up to 4 treatments, or until until ulcer closure, whichever occurs first.

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: The sham injections will be made by pressing on the ulcer with a needle connected to an empty syringe, at each cm of the ulcer bed
Study: NCT02057965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal Stromal Cells
Description: Two doses of autologous bone marrow (BM) derived MSCs IV, 7 days apart, 6 and 7 weeks after transplantation. Doses of MSCs will be 1-2x10\^6 million MSCs per/kg body weight
Study: NCT01349673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Foam
Description: Topical
Study: NCT04186325

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DIAPHRAGMATIC exercising
Description: inspiratory muscle training (IMT) will be initiated starting from the first ICU day. IMT will be conducted for 10 minutes two sessions per day, with an initial load of 30% of the maximum inspiratory pressure (MIP) measured immediately after changing patients to pressure support mode, and increased up to 40% in the second 5 minutes if tolerated by the patient. In addition, these patients received the usual care of MV patients.
Study: NCT02383862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feedback Group
Description: The intervention will consist of feedback provided to clinicians in the form of patients' baseline PROMIS scores
Study: NCT02818465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vascular calcifications by Xray

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vascular calcifications by tomodentimetry

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample withdrawn
Study: NCT02135068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic MiniMed Closed Loop (CL) System
Description: The Medtronic MiniMed Closed Loop (CL) System is an investigational system that uses some commercially available products. An investigational Enlite 2 glucose sensor measures the sensor glucose. The glucose sensor signal is sent to the insulin pump. From the insulin pump the sensor glucose is sent through the translator, which then relays the signal on to a controller. An Android Mobile Device (off the shelf) has the control algorithm installed. This device is known as the controller. The controller serves as the control center for the Android system, receiving data from the sensor and pump components, feeding the data to its control algorithm, issuing delivery commands to the pump to apply the algorithm's recommend therapy, and providing a means to monitor the system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic MiniMed Closed Loop (CL) System
Description: The Medtronic MiniMed Closed Loop (CL) System is an investigational system that uses some commercially available products. An investigational Enlite 2 glucose sensor measures the sensor glucose. The glucose sensor signal is sent to the insulin pump. From the insulin pump the sensor glucose is sent through the translator, which then relays the signal on to a controller. An Android Mobile Device (off the shelf) has the control algorithm installed. This device is known as the controller. The controller serves as the control center for the Android system, receiving data from the sensor and pump components, feeding the data to its control algorithm, issuing delivery commands to the pump to apply the algorithm's recommend therapy, and providing a means to monitor the system.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Snacking
Description: Up to 45 g of oral glucose via Gatorade
Study: NCT04403308

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONO-7913
Description: ONO-7913 will be administered by intravenous continuous infusion during the designated time.
Study: NCT01810900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Protescal
Study: NCT01641757

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-surgical periodontal therapy
Description: dental scaling and root planing of full mouth will be done
Study: NCT04552431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Ciprofloxacin, 500 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Ciprofloxacin, 500 mg twice daily
Study: NCT02438033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Activa PC+S Sensing Deep Brain Stimulator Generator
Description: Patients undergoing deep brain stimulation for Parkinson's disease based on clinically indicated criteria will have the option to enroll in this study, in which the Activa PC+S generator and corresponding extension leads will be implanted rather than the standard Activa PC system. Patients will be assessed every month for 3 months and then every 3 months after, including off and on medication assessments.
Study: NCT03706365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate
Description: Administered orally.
Study: NCT04552431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin Hydrochloride
Description: Tamsulosin Hydrochloride, 0.4 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin Hydrochloride
Description: Tamsulosin Hydrochloride, 0.4 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin Hydrochloride Placebo
Description: Tamsulosin Hydrochloride Placebo (Placebo-TH) one tablet once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tamsulosin Hydrochloride Placebo
Description: Tamsulosin Hydrochloride Placebo (Placebo-TH) one tablet once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ciprofloxacin placebo
Description: Ciprofloxacin placebo (Placebo-CF) one tablet twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin placebo
Description: Ciprofloxacin placebo (Placebo-CF) one tablet twice daily
Study: NCT01575899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin-Amox/clav.
Description: Levofloxacin, 500 mg b.i.d., amoxicillin/clavulanate, 875mg/125mg b.i.d. and rabeprazole, 20 mg b.i.d. for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin-Amoxicillin
Description: Clarithromycin, 500 mg b.i.d., amoxicillin, 1000 mg b.i.d. and rabeprazole 20 mg b.i.d. for 7 days.
Study: NCT04871685

Intervention type: DIAGNOSTIC_TEST
Intervention: lung ultrasound
Description: the patients underwent to a non invasive diagnostic exam to identify and monitor clinical conditions and onset of respiratory complications due to COVID-19

Intervention type: DIAGNOSTIC_TEST
Intervention: lung ultrasound
Description: the patients underwent to a non invasive diagnostic exam to identify and monitor clinical conditions and onset of respiratory complications due to COVID-19

Intervention type: DIAGNOSTIC_TEST
Intervention: lung ultrasound
Description: the patients underwent to a non invasive diagnostic exam to identify and monitor clinical conditions and onset of respiratory complications due to COVID-19
Study: NCT06309732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 50mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 37.5mg/m2
Study: NCT02087397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liposuction
Description: Liposuction using aspiration syringe and tumescent local anesthesia

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AD-SVF Cell Injection
Description: Stem cell implantation will be performed using direct injection into the Corpus Cavernosum with local anesthesia
Study: NCT03980496

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Study: NCT01891084

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Paracetamol 1 tablet (500mg) four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets (1gm) in each dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: (Identical-looking) Placebo 1 tablet four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets in each dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Backup NSAID ibuprofen
Description: Backup NSAID ibuprofen 200mg orally every 8 hourly will also be provided to all participants, which can be taken when necessary (PRN) if the participant finds the fever intolerable.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Backup NSAID ibuprofen
Description: Backup NSAID ibuprofen 200mg orally every 8 hourly will also be provided to all participants, which can be taken when necessary (PRN) if the participant finds the fever intolerable.
Study: NCT03283371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: As specified in the treatment arm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: As specified in treatment arms.
Study: NCT02204982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: PI3K Inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo (25 mg BID) administered orally in 28-day continuous treatment cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV infusion of rituximab (375 mg/m2) once weekly for 4 weeks during Cycle 1, then once on Day 1 of Cycles 4, 6, 8, and 10.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: IV infusion of rituximab (375 mg/m2) once weekly for 4 weeks during Cycle 1, then once on Day 1 of Cycles 4, 6, 8, and 10.
Study: NCT01284075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided imagery and music therapy
Description: Participants will undergo a standardized regimen of peri-operative guided imagery and music therapy guided by CDs (compact disc). The peri-operative regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: White Noise
Description: Control group (WN) will listen to a CD with white noise. Participants' regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: Control group (CP) will have no intervention at all and will follow our current peri-operative procedures.
Study: NCT00709423

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxaverine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxaverin 150mg
Description: intravenous administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: intravenous administration
Study: NCT00623987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin accordingly INR value
Description: warfarin accordingly to INR value between 2.0-3.0
Study: NCT05700487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PELVIC FLOOR EXERCISES
Description: Regular Pelvic floor exercises was performed three times a day for six months in the postoperative period
Study: NCT02546453

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Tumoral specific genetic alterations
Description: A buccal swab and a blood sample will be used at the diagnostic to identify the specific genetic alterations of tumoral cells.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Tumoral specific genetic alterations
Description: Collection of blood (maximum 9 samples of 3 to 5 ml), bone marrow (maximum 3 samples of 3 to 5 ml) and cerebral spinal fluid (maximum 3 samples 500µl to 1ml).
Study: NCT04871685

Intervention type: DIAGNOSTIC_TEST
Intervention: lung ultrasound
Description: the patients underwent to a non invasive diagnostic exam to identify and monitor clinical conditions and onset of respiratory complications due to COVID-19

Intervention type: DIAGNOSTIC_TEST
Intervention: lung ultrasound
Description: the patients underwent to a non invasive diagnostic exam to identify and monitor clinical conditions and onset of respiratory complications due to COVID-19
Study: NCT04310618

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00658749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIR645
Description: AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic saline solution
Description: Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
Study: NCT04871685

Intervention type: DIAGNOSTIC_TEST
Intervention: lung ultrasound
Description: the patients underwent to a non invasive diagnostic exam to identify and monitor clinical conditions and onset of respiratory complications due to COVID-19
Study: NCT03867461

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adjustment to end-tidal carbon dioxide concentrations ( 38-40 mmHg range)
Description: End-tidal carbon dioxide concentrations will be adjusted to fall in the End-tidal carbon dioxide concentrations will be adjusted to fall in the 38-40 mmHg range

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adjustment to end-tidal carbon dioxide concentrations ( 38-40 mmHg range)
Description: End-tidal carbon dioxide concentrations will be adjusted to fall in the End-tidal carbon dioxide concentrations will be adjusted to fall in the 38-40 mmHg range
Study: NCT03706365

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered orally.
Study: NCT03867461

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adjustment to Mean Arterial Pressure (100-110 mmHg range)
Description: Mean arterial pressure will be adjusted to fall in the 100-110 mmHg range

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adjustment to Mean Arterial Pressure (100-110 mmHg range)
Description: Mean arterial pressure will be adjusted to fall in the 100-110 mmHg range
Study: NCT03706365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT01941771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm B Vinorelbine (Navelbine oral) Capecitabine (Xeloda)
Description: Oral Vinorelbine (Navelbine oral) 50 mg 3 times weekly, monday, wednesday and friday plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1-14 in a 3 weekly schedule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm A Vinorelbine (Navelbine oral) Capecitabine (Xeloda)
Description: Vinorelbine (Navelbine Oral) 60 mg/m2 day 1 and day 8 Plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1 to 14 in a 3 weekly schedule.
Study: NCT00176124

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: leukocyte depletion of whole blood
Study: NCT02085421

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Transcranial direct current stimulation (tDCS) is a form of non-invasive neuromodulation that has been shown to enhance learning. tDCS is applied with current intensity of 1-2 mA of direct current and can be applied both before and during each cognitive remediation treatment session. Two saline soaked electrode sponges will be applied to the scalp.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Transcranial direct current stimulation (tDCS) is a form of non-invasive neuromodulation that has been shown to enhance learning. tDCS is applied with current intensity of 1-2 mA of direct current and can be applied both before and during each cognitive remediation treatment session. Two saline soaked electrode sponges will be applied to the scalp.
Study: NCT00176124

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leukocyte depletion of whole blood
Study: NCT03867461

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adjustment to Mean Arterial Pressure (100-110 mmHg range)
Description: Mean arterial pressure will be adjusted to fall in the 100-110 mmHg range
Study: NCT01770405

Intervention type: DEVICE
Intervention: Endoscopic ultrasound fine needle aspiration
Description: Device: nCLE needle-based Confocal Laser Endomicroscopy
Study: NCT02234440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Study: NCT04361292

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: INTRAUTERINE INSEMINATION
Description: Intrauterine insemination (IUI) combined with ovarian stimulation, has been an extensively used procedure for the treatment of patients with unexplained infertility. The fact that IUI is less expensive, less invasive, and easier to perform than other assisted reproductive techniques makes it the first-line treatment option in infertility treatments. Sperm that have been washed and concentrated are placed directly into the uterus around the time of ovulation. All patients had ovulation induction with gonadotropins and ovulation was triggered by recombinant hcg.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: INTRAUTERINE INSEMINATION
Description: Intrauterine insemination (IUI) combined with ovarian stimulation, has been an extensively used procedure for the treatment of patients with unexplained infertility. The fact that IUI is less expensive, less invasive, and easier to perform than other assisted reproductive techniques makes it the first-line treatment option in infertility treatments. Sperm that have been washed and concentrated are placed directly into the uterus around the time of ovulation. All patients had ovulation induction with gonadotropins and ovulation was triggered by recombinant hcg.
Study: NCT00176124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leukocyte filtration/Depletion
Description: leukocyte depletion filters as used routinely: filters (prestorage) inherent to the blood bag sets by gravity force following storage on cold plate for 2 hours